Formulation: A solid
Formal Name: L-histidyl-1-aminocyclobutanecarbonyl-L-glutaminylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-tyrosyl-L-seryl-L-lysyl-L-tyrosyl-L-leucyl-L-α-aspartyl-L-α-glutamyl-L-arginyl-L-alanyl-L-alanyl-L-lysyl-L-α-aspartyl-L-phenylalanyl-L-isoleucyl-N6-[N-(17-carboxy-1-oxoheptadecyl)-L-γ-glutamylglycyl-L-serylglycyl-L-serylglycylglycyl]-L-lysyl-L-tryptophyl-L-leucyl-L-α-glutamyl-L-seryl-L-alaninamide
Purity: ≥98%
Formula Markup: C192H289N47O61
Formula Weight: 4231,7
Shelf life (days): 1460
CAS Number: 2805997-46-8
Notes: Survodutide is a dual peptide agonist of the glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR).{72441} It increases cAMP accumulation in CHO-K1 cells expressing GLP-1R or GCGR in reporter assays (EC50s = 0.33 and 0.52 nM, respectively) and potentiates glucose-induced insulin secretion in isolated mouse, rat, and perifused human pancreatic islets. Survodutide (3 and 30 nmol/kg per day) reduces body weight and food intake in diet-induced obese mice, but the reduction in food intake diminishes over time and returns to baseline within approximately 15 days. It reduces the levels of hepatic triglycerides and cholesterol, as well as plasma levels of glucagon, cholesterol, triglycerides, alanine transaminase (ALT), aspartate aminotransferase (AST), insulin, and leptin in the same mice. Survodutide (10 nmol/kg per day) also increases energy expenditure in diet-induced obese mice.
English
Deutsch
